Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

References

• Bosch F, Lopez-Guillermo A, Campo E, Ribera J M, Conde E, Piris M A, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567–575
   PubMed Web of Science ®Google Scholar
• Campo E, Raffeld M, Jaffe E S. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115–127
   PubMed Web of Science ®Google Scholar
• Evans L S, Hancock B W. Non-Hodgkin lymphoma. Lancet 2003; 362: 139–146
   PubMed Web of Science ®Google Scholar
• Fisher R I, Dahlberg S, Nathwani B N, Banks P M, Miller T P, Grogan T M. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995; 85: 1075–1082
   PubMed Web of Science ®Google Scholar
• Ritchie D S, Seymour J F, Grigg A P, Roberts A W, Hoyt R, Thompson S, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007; 86: 101–105
   PubMed Web of Science ®Google Scholar
• Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Antal D, Lacotte-Thierry L, Delwail V, Espinouse D, Michallet A S, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005; 104: 1434–1441
   PubMed Web of Science ®Google Scholar
• Vigouroux S, Gaillard F, Moreau P, Harousseau J L, Milpied N. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 2005; 90: 1580–1582
   PubMed Web of Science ®Google Scholar
• Zelenetz A D. Mantle cell lymphoma: an update on management. Ann Oncol 2006; 17(Suppl 4)iv12–iv14
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger D D, Greiner T C, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathological study based on gene expression profiling. Blood 2005; 106: 4315–4321
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, Chan W C, Connors J M, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185–197
   PubMed Web of Science ®Google Scholar
• Katzenberger T, Petzoldt C, Holler S, Mader U, Kalla J, Adam P, et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006; 107: 3407
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, Dreyling M H, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29–38
   PubMed Web of Science ®Google Scholar
• Argatoff L H, Connors J M, Klasa R J, Horsman D E, Gascoyne R D. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067–2078
   PubMed Web of Science ®Google Scholar
• de Vos S, Krug U, Hofmann W K, Pinkus G S, Swerdlow S H, Wachsman W, et al. Cell cycle alterations in the blastoid variant of mantle cell lymphoma (MCL-BV) as detected by gene expression profiling of mantle cell lymphoma (MCL) and MCL-BV. Diagn Mol Pathol 2003; 12: 35–43
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hollmen J, Raty R, Aalto Y, Nagy B, Elonen E, et al. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 2002; 119: 905–915
   PubMed Web of Science ®Google Scholar
• Bachmann M, Hennemann H, Xing P X, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004; 279: 48319–48328
   PubMed Web of Science ®Google Scholar
• Bachmann M, Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 2005; 37: 726–730
   PubMed Web of Science ®Google Scholar
• Hu Y L, Passegue E, Fong S, Largman C, Lawrence H J. Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood 2007; 109: 4732–4738
   PubMed Web of Science ®Google Scholar
• Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004; 24: 6104–6115
   PubMed Web of Science ®Google Scholar
• Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007; 9: 932–944
   PubMed Web of Science ®Google Scholar
• Feldman J D, Vician L, Crispino M, Tocco G, Marcheselli V L, Bazan N G, et al. KID-1, a protein kinase induced by depolarization in brain. J Biol Chem 1998; 273: 16535–16543
   PubMed Web of Science ®Google Scholar
• van der Lugt N M, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J, et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995; 14: 2536–2544
   PubMed Web of Science ®Google Scholar
• Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, Gapter L, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001; 2: 167–179
   PubMedGoogle Scholar
• Chen X P, Losman J A, Cowan S, Donahue E, Fay S, Vuong B Q, et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci USA 2002; 99: 2175–2180
   PubMed Web of Science ®Google Scholar
• Kim K T, Levis M, Small D. Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br J Haematol 2006; 134: 500–509
   PubMed Web of Science ®Google Scholar
• Leverson J D, Koskinen P J, Orrico F C, Rainio E M, Jalkanen K J, Dash A B, et al. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. Mol Cell 1998; 2: 417–425
   PubMed Web of Science ®Google Scholar
• Lilly M, Sandholm J, Cooper J J, Koskinen P J, Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999; 18: 4022–4031
   PubMed Web of Science ®Google Scholar
• Peltola K J, Paukku K, Aho T L, Ruuska M, Silvennoinen O, Koskinen P J. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 2004; 103: 3744–3750
   PubMed Web of Science ®Google Scholar
• Rainio E M, Sandholm J, Koskinen P J. Cutting edge: transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol 2002; 168: 1524–1527
   PubMed Web of Science ®Google Scholar
• Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989; 86: 8857–8861
   PubMed Web of Science ®Google Scholar
• Dhanasekaran S M, Barrette T R, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822–826
   PubMed Web of Science ®Google Scholar
• Domen J, van der Lugt N M, Laird P W, Saris C J, Berns A. Analysis of Pim-1 function in mutant mice. Leukemia 1993; 7(Suppl 2)S108–S112
   PubMed Web of Science ®Google Scholar
• van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989; 56: 673–682
   PubMed Web of Science ®Google Scholar
• Ellwood-Yen K, Graeber T G, Wongvipat J, Iruela-Arispe M L, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4: 223–238
   PubMed Web of Science ®Google Scholar
• Damon L E, Johnson J, Niedzwiecki D, Cheson B D, Hurd D D, Bartlett N L, et al. Immuno-chemotherapy and autologous stem cell transplant for untreated patients with mantle cell lymphoma: CALGB 59909. Blood 2006; 108: 774a
   PubMed Web of Science ®Google Scholar
• Jung S H, Owzar K, George S L. A multiple testing procedure to associate gene expression levels with survival. Stat Med 2005; 24: 3077–3088
   PubMed Web of Science ®Google Scholar
• Nodit L, Bahler D W, Jacobs S A, Locker J, Swerdlow S H. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003; 34: 1030–1034
   PubMed Web of Science ®Google Scholar
• Vandenberghe E, Wolf-Peeters C, Vaughan Hudson G, Vaughan Hudson B, Pittaluga S, Anderson L, et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997; 99: 842–847
   PubMed Web of Science ®Google Scholar
• Lardelli P, Bookman M A, Sundeen J, Longo D L, Jaffe E S. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 1990; 14: 752–763
   PubMed Web of Science ®Google Scholar
• Hui D, Reiman T, Hanson J, Linford R, Wong W, Belch A, et al. Immunohistochemical detection of cdc2 is useful in predicting survival in patients with mantle cell lymphoma. Mod Pathol 2005; 18: 1223–1231
   PubMed Web of Science ®Google Scholar
• Chiarle R, Budel L M, Skolnik J, Frizzera G, Chilosi M, Corato A, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95: 619–626
   PubMed Web of Science ®Google Scholar
• Greiner T C, Moynihan M J, Chan W C, Lytle D M, Pedersen A, Anderson J R, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87: 4302–4310
   PubMed Web of Science ®Google Scholar
• Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado M A, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996; 87: 3351–3359
   PubMed Web of Science ®Google Scholar
• Kienle D, Katzenberger T, Ott G, Saupe D, Benner A, Kohlhammer H, et al. Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J Clin Oncol 2007; 25: 2770–2777
   PubMed Web of Science ®Google Scholar
• Salaverria I, Zettl A, Bea S, Moreno V, Valls J, Hartmann E, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007; 25: 1216–1222
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, Gisselbrecht C, Van Hoof A, Kluin-Nelemans H C, et al. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2007; 111: 558–565
   PubMed Web of Science ®Google Scholar
• Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002; 69: 11–20
   PubMed Web of Science ®Google Scholar
• Schrader C, Meusers P, Brittinger G, Teymoortash A, Siebmann J U, Janssen D, et al. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome. Leukemia 2004; 18: 1200–1206
   PubMed Web of Science ®Google Scholar
• Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111: 2385–2387
   PubMed Web of Science ®Google Scholar
• Hilbe W, Gachter A, Duba H C, Dirnhofer S, Eisterer W, Schmid T, et al. Comparison of automated cellular imaging system and manual microscopy for immunohistochemically stained cryostat sections of lung cancer specimens applying p53, ki-67 and p120. Oncol Rep 2003; 10: 15–20
   PubMed Web of Science ®Google Scholar
• van Sandick J W, Baak J P, van Lanschot J J, Polkowski W, ten Kate F J, Obertop H, et al. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus. J Pathol 2000; 190: 177–183
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications – a study from the Lunenburg lymphoma biomarker consortium. J Clin Oncol 2007; 25: 805–812
   PubMed Web of Science ®Google Scholar
• Holder S, Zemskova M, Zhang C, Tabrizizad M, Bremer R, Neidigh J W, et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007; 6: 163–172
   PubMed Web of Science ®Google Scholar
• Wang Z, Bhattacharya N, Mixter P F, Wei W, Sedivy J, Magnuson N S. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45–55
   PubMed Web of Science ®Google Scholar
• Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998; 17: 931–939
   PubMed Web of Science ®Google Scholar
• Aho T L, Sandholm J, Peltola K J, Mankonen H P, Lilly M, Koskinen P J. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004; 571: 43–49
   PubMed Web of Science ®Google Scholar
• Shirogane T, Fukada T, Muller J M, Shima D T, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999; 11: 709–719
   PubMed Web of Science ®Google Scholar
• Shay K P, Wang Z, Xing P X, McKenzie I F, Magnuson N S. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res 2005; 3: 170–181
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 1999; 274: 18659–18666
   PubMed Web of Science ®Google Scholar
• Fox C J, Hammerman P S, Thompson C B. The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 2005; 201: 259–266
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti R S, Kuppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412: 341–346
   PubMed Web of Science ®Google Scholar
• Goy A. Mantle cell lymphoma: evolving novel options. Curr Oncol Rep 2007; 9: 391–398
   PubMedGoogle Scholar
• Khouri I F, Romaguera J, Kantarjian H, Palmer J L, Pugh W C, Korbling M, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803–3809
   PubMed Web of Science ®Google Scholar